NCT04877522 - Asciminib Roll-over Study | Biotech Hunter

Enrollment

347

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

August 29, 2030

Study Completion Date

August 30, 2030

Conditions

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG

Asciminib single agent

Taken orally, twice daily (BID) or once daily (QD), in fasting state

DRUG

Imatinib

Taken orally, once daily, in the morning with low-fat meal

DRUG

Nilotinib

Taken orally, twice daily, on an empty stomach

DRUG

Bosutinib

Taken orally, once daily, with food

DRUG

Dasatinib

Taken orally, once daily in a fasted state, 1 or 2 hours before a meal

DRUG

Asciminib single agent pediatric formulation

Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.

Trial Locations (83)

123

RECRUITING

Novartis Investigative Site, Khoudh

1140

RECRUITING

Novartis Investigative Site, Vienna

8036

RECRUITING

Novartis Investigative Site, Graz

9000

RECRUITING

Novartis Investigative Site, Varna

10017

RECRUITING

Memorial Sloan Kettering, New York

10450

RECRUITING

Novartis Investigative Site, George Town

11211

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Riyadh

11759

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Uijeongbu-si

13273

RECRUITING

Novartis Investigative Site, Marseille

13353

RECRUITING

Novartis Investigative Site, Berlin

15706

RECRUITING

Novartis Investigative Site, Santiago Compostela

20162

RECRUITING

Novartis Investigative Site, Milan

24116

RECRUITING

Novartis Investigative Site, Kiel

28006

RECRUITING

Novartis Investigative Site, Madrid

28034

RECRUITING

Novartis Investigative Site, Madrid

28041

RECRUITING

Novartis Investigative Site, Madrid

33076

RECRUITING

Novartis Investigative Site, Bordeaux

33305

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Taoyuan District

38009

RECRUITING

Novartis Investigative Site, Santa Cruz

41009

RECRUITING

Novartis Investigative Site, Seville

44093

RECRUITING

Novartis Investigative Site, Nantes

46026

RECRUITING

Novartis Investigative Site, Valencia

48013

RECRUITING

Novartis Investigative Site, Bilbao

49201

COMPLETED

Novartis Investigative Site, Busan

54511

RECRUITING

Novartis Investigative Site, Vandœuvre-lès-Nancy

55200

RECRUITING

Novartis Investigative Site, Samsun

60590

RECRUITING

Novartis Investigative Site, Frankfurt am Main

64460

RECRUITING

Novartis Investigative Site, Monterrey

68000

RECRUITING

Novartis Investigative Site, Kuala Selangor

69373

RECRUITING

Novartis Investigative Site, Lyon

75475

RECRUITING

Novartis Investigative Site, Paris

77030

RECRUITING

Uni Of TX MD Anderson Cancer Cntr, Houston

80100

RECRUITING

Novartis Investigative Site, Johor Bahru

80131

COMPLETED

Novartis Investigative Site, Napoli

97239

ACTIVE_NOT_RECRUITING

Oregon Health Sciences University, Portland

100000

RECRUITING

Novartis Investigative Site, Hanoi

100044

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Beijing

100730

RECRUITING

Novartis Investigative Site, Beijing

110004

RECRUITING

Novartis Investigative Site, Shenyang

125167

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Moscow

125284

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Moscow

130021

RECRUITING

Novartis Investigative Site, Changchun

169608

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Singapore

191024

RECRUITING

Novartis Investigative Site, Saint Petersburg

197341

RECRUITING

Novartis Investigative Site, Saint Petersburg

200025

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Shanghai

300020

RECRUITING

Novartis Investigative Site, Tianjin

300079

RECRUITING

Novartis Investigative Site, Timișoara

400010

RECRUITING

Novartis Investigative Site, Chongqing

430022

RECRUITING

Novartis Investigative Site, Wuhan

450008

RECRUITING

Novartis Investigative Site, Zhengzhou

510515

RECRUITING

Novartis Investigative Site, Guangzhou

519763

COMPLETED

Novartis Investigative Site, Jeollanam

610041

RECRUITING

Novartis Investigative Site, Chengdu

710004

RECRUITING

Novartis Investigative Site, Xian

738000

RECRUITING

Novartis Investigative Site, Ho Chi Minh City

48109 5271

RECRUITING

Michigan Med University of Michigan, Ann Arbor

C1221ADC

RECRUITING

Novartis Investigative Site, CABA

C1114AAN

RECRUITING

Novartis Investigative Site, Capital Federal

20211-030

RECRUITING

Novartis Investigative Site, Rio de Janeiro

05403 000

RECRUITING

Novartis Investigative Site, São Paulo

08270-070

RECRUITING

Novartis Investigative Site, São Paulo

H1T 2M4

RECRUITING

Novartis Investigative Site, Montreal

708 52

RECRUITING

Novartis Investigative Site, Ostrava

625 00

RECRUITING

Novartis Investigative Site, Brno

DK-2100

COMPLETED

Novartis Investigative Site, Copenhagen

07740

RECRUITING

Novartis Investigative Site, Jena

00161

RECRUITING

Novartis Investigative Site, Roma

650-0017

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Kobe

113-0236

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Beirut

40-519

RECRUITING

Novartis Investigative Site, Katowice

30-688

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Krakow

00-791

RECRUITING

Novartis Investigative Site, Warsaw

50 367

COMPLETED

Novartis Investigative Site, Wroclaw

1099-023

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Lisbon

4200-072

RECRUITING

Novartis Investigative Site, Porto

03080

RECRUITING

Novartis Investigative Site, Seoul

08907

RECRUITING

Novartis Investigative Site, L'Hospitalet de Llobregat

08916

RECRUITING

Novartis Investigative Site, Badalona

08035

RECRUITING

Novartis Investigative Site, Barcelona

08036

RECRUITING

Novartis Investigative Site, Barcelona

W12 0HS

RECRUITING

Novartis Investigative Site, London

OX3 7LE

RECRUITING

Novartis Investigative Site, Oxford